摘要
本文应用碘标记的表皮生长因子(^(125)I-EGF),用分步离心提取癌细胞膜蛋白,以标准的EGF作竞争剂,采取放射标记结合法测定了40例乳腺癌组织中的表皮生长因子受体(EGFR)水平,同时采用葡聚糖活性碳分析法(DCC)测定了乳腺癌组织中的雌激素受体(ER)、孕激素受体(PR)以探讨EGFR表达与ER、PR在乳腺癌组织中的生物学行为及相互关系。实验结果表明,EGPR≥10fmlo/mg膜蛋白作为阳性,ER、PR也以≥10fmol/mg蛋白作为阳性,EGFR水平位于1～183fmol/mg之间阳性率为42.5％,ER的阳性率为55％,PR阳性率为22.5％,EGFR的阳性率与乳腺癌组织学类型、年龄等无关,但与ER、PR之间有关,在ER阳性组(ER^+)、PR阳性组(PR^+)中EGFR阴性(EGFR^-)例数较多,有显著差别,EGFR^-组为6/9(66％),在单独一项ER^+组别中,EGFR^-比例高14/22(63％),也呈负相关关系,但在ER^-组中与EGF^+组未见差别。说明雌激素受体在乳腺癌中起着关键的作用,高含量的ER可能在某些环节上抑制了EGFR的表达,这需要进一步加以证实。
The aim of the study was to quantitate the RFG binding to breast cancer tissue and compare with that of oestrogen, and progesterone. EGFR, ER, PR concentrations were determined by radioligand bind assay in 40 specimens of primary breast cancer tissue taking values>10 fmol/mg membrance protein to be positive for each of the parameters. EGRF levels were found to be 1-183 fmol/mg, and positive rate were 42.5%; positive rate for GR was 55% and22.5% for PR. found to be. There was no correlation between EGFR and histology type of breast cancer. However, there seemed to be an inverse relationship between ER( + ),PR( + ) group and EGFR( - ) group. Single ER( + ) group also had inverse relationship with EGFR( - ) group. Our data suggest that high levels of ER may inhibite the express of EGFR in breast cancetissue. The findings need further investigation.
出处
《放射免疫学杂志》
CAS
1998年第1期4-6,共3页
Journal of Radioimmanology
